Ambryon Biosciences

Human phosphoglycerate kinase 1 (PGK1) promoter

Housekeeping promoter from the human PGK1 gene, constitutively active in dividing and non-dividing mammalian cells. Provides moderate, stable expression with lower immunogenicity than viral promoters. Commonly used to drive selectable markers, Cre recombinase, and reporter transgenes in lentiviral and AAV vectors.

Relative StrengthModerate
OriginHuman PGK1 gene 5′-flanking region (natural)
Expression PatternConstitutive

Characteristics

450 bp of 5'-flanking sequence plus the leader, first exon, and part of intron 1 of the human PGK1 gene, first sequenced by Singer-Sam et al. (1984); the fragment commonly used to drive expression spans approximately positions -528 to -13 relative to the ATG (Kita-Matsuo et al. 2009). Drives ubiquitous, moderate-level constitutive expression; in lentivirally transduced human embryonic stem cell-derived cardiomyocytes and progenitors, unsorted populations show transgene silencing that progressively drops the fraction of fluorescent-positive cells from >80% to <5% by passage 6, requiring FACS enrichment or clonal selection for stable long-term reporter lines (Kita-Matsuo et al. 2009). Expression is constitutive in both dividing and non-dividing cells.

Applications

Drives H2B-fluorescent reporter fusions and drug-resistance selection cassettes (Blasticidin, Neomycin, Puromycin) in lentiviral vectors for tracking and purifying human embryonic stem cell-derived cardiomyocytes, yielding >96% pure cardiomyocyte populations after dual selection (Kita-Matsuo et al. 2009); also used to drive selectable markers and Cre recombinase in lentiviral and AAV vectors.

Limitations

Unsorted lentiviral populations progressively silence PGK-driven transgene expression, falling from >80% to <5% fluorescent-positive cells by passage 6 without FACS enrichment or clonal selection (Kita-Matsuo et al. 2009); weaker than strong viral or CAG-type promoters when maximal expression level is required.

Sequence505 bp

Sign in to view the full sequence.

Sign in

References

  1. 1.Kita-Matsuo et al. (2009). Lentiviral Vectors and Protocols for Creation of Stable hESC Lines for Fluorescent Tracking and Drug Resistance Selection of Cardiomyocytes. PLoS ONE — Kita-Matsuo 2009 hESC Cardiomyocyte

Identifiers & revision